Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA® in UK clinical practice

Bayer HealthCare reports that real-world data from a UK wide National Aflibercept Audit and Moorfields Aflibercept Audit have been presented at The Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD). The results from both audits highlight that treatment with aflibercept in NHS clinical practice has resulted in stabilised or improved visual and/or anatomical outcomes in treatment-naïve and pre-treated patients; (1–4) reflecting the results seen in the pivotal VIEW clinical trials. (5)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Association News Clinical trials Practical therapeutics Industry News Other conferences & symposia Ophthalmology aflibercept ARVO 2015 EYLEA Latest News VIEW clinical trial wAMD wet age-related macular degen Source Type: news